• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Vaccinated patients have reduced rates of hospitalization after receiving casirivimab and imdevimab for COVID-19.

作者信息

Zitek Tony, Jodoin Kathleen, Kheradia Tarang, Napolillo Ryan, Dalley Michael T, Quenzer Faith, Farcy David A

机构信息

Department of Emergency Medicine, Mount Sinai Medical Center, 4300 Alton Road, Miami Beach, FL 33140, United States of America; Department of Emergency Medicine, Herbert Wertheim College of Medicine, 11200 SW 8th St, Miami, FL 33199, United States of America.

Department of Pharmacy, Mount Sinai Medical Center, 4300 Alton Road, Miami Beach, FL 33140, United States of America.

出版信息

Am J Emerg Med. 2022 Jun;56:370-371. doi: 10.1016/j.ajem.2021.10.044. Epub 2021 Nov 2.

DOI:10.1016/j.ajem.2021.10.044
PMID:34763963
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8562033/
Abstract
摘要

相似文献

1
Vaccinated patients have reduced rates of hospitalization after receiving casirivimab and imdevimab for COVID-19.接种疫苗的患者在接受卡西瑞维单抗和英地维单抗治疗新冠肺炎后，住院率有所降低。
Am J Emerg Med. 2022 Jun;56:370-371. doi: 10.1016/j.ajem.2021.10.044. Epub 2021 Nov 2.
2
Breakthrough COVID-19 and casirivimab-imdevimab treatment during a SARS-CoV-2 B1.617.2 (Delta) surge.突破性 COVID-19 与 SARS-CoV-2 B.1.617.2 (Delta) 变异株流行期间使用 casirivimab-imdevimab 治疗
J Clin Virol. 2021 Dec;145:105026. doi: 10.1016/j.jcv.2021.105026. Epub 2021 Nov 8.
3
Impact of COVID vaccine and comorbidities in patients receiving casirivimab-imdevimab monoclonal antibody during SARS-CoV-2 B.1.617.2 (Delta) surge: A real-world study.新冠病毒 B.1.617.2（德尔塔）变异株流行期间接受 casirivimab-imdevimab 单克隆抗体治疗的患者中新冠疫苗和合并症的影响：一项真实世界研究。
Vaccine. 2023 Aug 7;41(35):5195-5200. doi: 10.1016/j.vaccine.2023.07.011. Epub 2023 Jul 13.
4
SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19.SARS-CoV-2 中和单克隆抗体预防 COVID-19。
Cochrane Database Syst Rev. 2022 Jun 17;6(6):CD014945. doi: 10.1002/14651858.CD014945.pub2.
5
Casirivimab/imdevimab treatment for outpatient COVID-19 during a SARS-CoV-2 B1.617.2 (Delta) surge at a community hospital.在一家社区医院，SARS-CoV-2 B1.617.2（德尔塔）毒株激增期间，卡西瑞维单抗/依米德维单抗用于门诊COVID-19治疗。
J Osteopath Med. 2022 Sep 20;122(12):635-640. doi: 10.1515/jom-2022-0070. eCollection 2022 Dec 1.
6
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.卡司瑞韦单抗和伊德韦单抗联合治疗住院 COVID-19 患者（RECOVERY）：一项随机、对照、开放标签、平台试验。
Lancet. 2022 Feb 12;399(10325):665-676. doi: 10.1016/S0140-6736(22)00163-5.
7
Association of Subcutaneous or Intravenous Administration of Casirivimab and Imdevimab Monoclonal Antibodies With Clinical Outcomes in Adults With COVID-19.卡司瑞韦单抗和伊德维单抗皮下注射或静脉给药与 COVID-19 成年患者临床结局的关联。
JAMA Netw Open. 2022 Apr 1;5(4):e226920. doi: 10.1001/jamanetworkopen.2022.6920.
8
Effectiveness of Casirivimab-Imdevimab and Sotrovimab During a SARS-CoV-2 Delta Variant Surge: A Cohort Study and Randomized Comparative Effectiveness Trial.在 SARS-CoV-2 德尔塔变异株流行期间 Casirivimab-Imdevimab 和 Sotrovimab 的有效性：一项队列研究和随机对照有效性试验。
JAMA Netw Open. 2022 Jul 1;5(7):e2220957. doi: 10.1001/jamanetworkopen.2022.20957.
9
Curbing the Delta Surge: Clinical Outcomes After Treatment With Bamlanivimab-Etesevimab, Casirivimab-Imdevimab, or Sotrovimab for Mild to Moderate Coronavirus Disease 2019.抑制德尔塔浪潮：巴姆洛单抗-埃特司韦单抗、卡司瑞韦单抗-伊德韦单抗或索特罗韦单抗治疗轻度至中度 2019 冠状病毒病的临床结局。
Mayo Clin Proc. 2022 Sep;97(9):1641-1648. doi: 10.1016/j.mayocp.2022.06.015. Epub 2022 Jun 23.
10
Noninferiority of Subcutaneous Versus Intravenous Casirivimab/Imdevimab for Outpatient Treatment of SARS-CoV-2 in a Real-World Setting.在真实环境中，皮下注射用卡司瑞韦单抗/伊德维单抗与静脉注射用卡司瑞韦单抗/伊德维单抗治疗门诊 SARS-CoV-2 患者的非劣效性。
Monoclon Antib Immunodiagn Immunother. 2022 Aug;41(4):210-213. doi: 10.1089/mab.2022.0008. Epub 2022 Aug 3.

引用本文的文献

1
A Descriptive, Retrospective Analysis of COVID-19 Passive Antibody Therapy and Its Effects on Morbidity and Mortality in Patients Receiving B-Cell-Depleting Therapies.新冠病毒被动抗体疗法及其对接受B细胞耗竭疗法患者发病率和死亡率影响的描述性回顾性分析
Diseases. 2024 Feb 6;12(2):33. doi: 10.3390/diseases12020033.
2
Retrospective Analysis of Vaccinated and Unvaccinated COVID-19 Patients Treated with Monoclonal Antibodies (mAb) and Their Emergent Needs (RAVEN).接种和未接种新冠疫苗的单克隆抗体治疗新冠患者及其紧急需求的回顾性分析（RAVEN）
Vaccines (Basel). 2023 Mar 17;11(3):688. doi: 10.3390/vaccines11030688.
3
Discrepancies in Outcomes by Race and Ethnicity in COVID-19 Patients Receiving Casirivimab and Imdevimab.接受卡司瑞韦单抗和伊德维单抗治疗的 COVID-19 患者中，种族和民族差异导致的结果差异。
South Med J. 2023 Jan;116(1):15-19. doi: 10.14423/SMJ.0000000000001498.
4
Real-World Use of Sotrovimab for Pre-Emptive Treatment in High-Risk Hospitalized COVID-19 Patients: An Observational Cross-Sectional Study.索托维单抗在高危住院COVID-19患者抢先治疗中的真实世界应用：一项观察性横断面研究。
Antibiotics (Basel). 2022 Mar 5;11(3):345. doi: 10.3390/antibiotics11030345.

本文引用的文献

1
Uptake of Outpatient Monoclonal Antibody Treatments for COVID-19 in the United States: a Cross-Sectional Analysis.美国门诊使用单克隆抗体治疗新冠病毒病的情况：一项横断面分析
J Gen Intern Med. 2021 Dec;36(12):3922-3924. doi: 10.1007/s11606-021-07109-5. Epub 2021 Sep 8.
2
A Comparison of SARS-COV-2 Neutralizing Antibody Therapies in High-Risk Patients with Mild to Moderate COVID-19 Disease at a Single Academic Hospital.单家学术医院轻至中度 COVID-19 疾病高危患者中 SARS-COV-2 中和抗体治疗的比较。
J Emerg Med. 2022 Jan;62(1):83-91. doi: 10.1016/j.jemermed.2021.07.025. Epub 2021 Jul 15.
3
Racial Disparities in COVID-19 Testing and Outcomes : Retrospective Cohort Study in an Integrated Health System.COVID-19 检测和结果的种族差异：综合卫生系统中的回顾性队列研究。
Ann Intern Med. 2021 Jun;174(6):786-793. doi: 10.7326/M20-6979. Epub 2021 Feb 9.
4
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19.REGN-COV2，一种中和抗体鸡尾酒疗法，用于治疗门诊新冠患者。
N Engl J Med. 2021 Jan 21;384(3):238-251. doi: 10.1056/NEJMoa2035002. Epub 2020 Dec 17.
5
Clinical profile and predictors of in-hospital mortality among older patients hospitalised for COVID-19.老年 COVID-19 住院患者院内死亡的临床特征和预测因素。
Age Ageing. 2021 Feb 26;50(2):326-334. doi: 10.1093/ageing/afaa258.
6
Racial and Ethnic Differences in Presentation and Outcomes for Patients Hospitalized With COVID-19: Findings From the American Heart Association's COVID-19 Cardiovascular Disease Registry.因 COVID-19 住院患者的临床表现和结局的种族和民族差异：美国心脏协会 COVID-19 心血管疾病登记研究的结果。
Circulation. 2021 Jun 15;143(24):2332-2342. doi: 10.1161/CIRCULATIONAHA.120.052278. Epub 2020 Nov 17.
7
Obesity a predictor of outcomes of COVID-19 hospitalized patients-A systematic review and meta-analysis.肥胖是 COVID-19 住院患者结局的预测因素：系统评价和荟萃分析。
J Med Virol. 2021 Feb;93(2):1188-1193. doi: 10.1002/jmv.26555. Epub 2020 Oct 7.
8
A brief-review of the risk factors for covid-19 severity.Covid-19 严重程度的危险因素简述。
Rev Saude Publica. 2020;54:60. doi: 10.11606/s1518-8787.2020054002481. Epub 2020 Jun 1.